Incidence and Impact of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis From the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM Trials

Cytokinetics Incorporated published this content on September 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 01, 2025 at 05:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]